Evotec
Maria Whatton is an accomplished Principal Scientist specializing in computational drug discovery at Evotec since September 2020, leading early-phase projects within the Molecular Architect department. Prior to this, Maria held various roles at Eli Lilly and Company, including Senior Research Scientist, where leadership of cross-functional teams resulted in pivotal scaffold recommendations and novel small molecule designs. With a solid foundation in medicinal chemistry and computational techniques, Maria has consistently applied innovative approaches in drug design, contributing to multiple patent publications. Educational qualifications include a Ph.D. and a Bachelor's Degree in Chemistry from Cardiff University, complemented by strong academic performance in earlier studies.
This person is not in any teams
This person is not in any offices
Evotec
5 followers
Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees, milestones and/or royalties. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The Company seeks to partner these into collaborations in return for upfront payments, ongoing research payments. It consists of all partnerships derived from its internally developed assets and platforms and its participations in certain companies. It includes clinical initiations and progress of clinical pipeline within partnerships; expansion of academic BRIDGE network; research and development (R&D) progress with CureX/Target X initiatives, and focuses on induced pluripotent stem cells (iPSC) platform.